Daré’s royalty deal; Qlaris Bio raises $24M

Plus, news about Newron and Syn­Ox:

Daré Bio­science inks roy­al­ty deal with XO­MA: The com­pa­ny re­ceived $22 mil­lion, which is ex­pect­ed to help progress a pair of women’s health ther­a­pies through Phase 3. Dare’s stock $DARE was up about 28% af­ter an­nounc­ing the agree­ment. — Jaimy Lee

Qlaris Bio se­cures $24M in Se­ries B: The pro­ceeds will sup­port the con­tin­ued de­vel­op­ment of the biotech’s Phase 2 as­set, QLS‑111, which is de­signed to low­er in­traoc­u­lar pres­sure in pa­tients with open-an­gle glau­co­ma and oc­u­lar hy­per­ten­sion. The fundraise was co-led by Canaan and New Leaf Ven­ture Part­ners. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.